Can Shield Bring More People into Colorectal Cancer Screening? ↗
Both involve Guardant Health, but screening and treatment selection are distinct uses and markets.
Evidence: Guardant Health ↗FDA ↗
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
Commercialization · TOPIC v2
Therapy & companion diagnostics
Where might linked diagnostic and therapy approvals stall in practice?
2026-09-07 11:00:45.083 UTC · Last recorded update
CURRENT READING
Concurrent approvals. Uptake and payment for the new use remain open.
Recorded editorial state, not a maturity score
- Drug & CDxRecorded
- UptakeUnverified
- PaymentUnverified
- Real-world useUnverified
Structure update, no new experiment · v1 → 2
Clustered issuer announcements around one regulatory event.
Permanent link to this revision ↗01 / WHAT WE TRACK
Where might linked diagnostic and therapy approvals stall in practice?
03 / EDITORIAL READING
Read drug and diagnostic approvals as a pathway, without treating approval as evidence of utilization or revenue.
04 / WHAT REMAINS UNKNOWN
Accelerated approval; OS immature. New-use reimbursement, uptake and incremental revenue are unverified.
05 / NEXT CHECK
Confirmatory trials, payer policies for the new use and clinical uptake.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDEmbedding diagnosis in treatment switching may expand value from a single test to longitudinal monitoring.
What would change our view: Reconsider if adoption barriers or payment terms prevent broader longitudinal use.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsCOMPANYGuardant Health ↗
Provider of Shield and Guardant360 CDx; distinct products and uses.
Evidence: Guardant Health ↗FDA ↗
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v2 · 2026-09-07 11:00:45.083 UTCStructure update, no new experiment
Clustered issuer announcements around one regulatory event.
Reading at the time: Concurrent approvals. Uptake and payment for the new use remain open.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Source-event timeline (different from editorial revisions)
- Recorded event
Accelerated approval of the Etcamah combination and concurrent CDx approval.
Sources: FDA ↗
Historical events were assembled through source research. They do not imply the magazine tracked them at the time.
Source dates and verification scope
Accelerated approval of camizestrant with a CDK4/6 inhibitor ↗
FDA · 2026-09-04 · regulator
Etcamah approved in the US for HR+ breast cancer ↗
AstraZeneca · 2026-09-04 · issuer